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PENILAIAN SIFAT-SIFAT PERLINDUNGAN NEURO BAGI  
EKSTRAK ETANOL ECHIUM AMOENUM L. 
ABSTRAK 
Dalam penyakit degeneratif neuro iskemia dan hipoksia, tekanan oksidatif, 
eksitotoksisiti dan keradangan semuanya boleh membawa kepada kehilangan neuron. 
Kematian sel ganglion akibat degenerasi saraf optik boleh disebabkan oleh kesakitan 
iskemia berselang-selang sepanjang tempoh yang ditetapkan. Perlindungan neuro 
bertujuan untuk mencegah, melambatkan atau menterbalikkan kerosakan neuron 
akibat daripada keadaan asas patofisiologi. Matlamat kerja ini adalah untuk menilai 
sifat-sifat perlindungan neuro daripada tumbuhan asli Iran Echium amoenum L.. 
Kajian telah dijalankan untuk menyimpulkan sama ada E. amoenum boleh 
menumpulkan pengaruh negatif kekurangan serum terhadap sel-sel ganglion retina 
(RGC-5) dalam kultur dan juga terhadap kesakitan iskemia tertakrif dalam saraf optik 
tikus. Anti-apoptotik, anti-oksidan, gerak balas angiogenik dan aktiviti-aktiviti anti-
radang semuanya disiasat. Kajian lanjut seterusnya dijalankan untuk mencirikan 
entiti perubatan aktif yang hadir dengan menggunakan Jisim Spektrometri-
Kromatografi Gas (GC/MS). Ekstrak kloroform, etanol, n-heksana, dan akueus 
daripada kelopak E. amoenum telah disediakan melalui teknik maserasi/pemaseratan 
dan disaring dengan titisan sel RGC-5 untuk sifat-sifat neurotoksiknya. Ekstrak 
etanol dan air adalah tidak toksik. Walau bagaimanapun kajian in vitro ischemia 
mendedahkan bahawa ekstrak etanol E.  amoenum pada 5 μg/mL adalah berkesan 
dalam menyelamatkan RGC-5 sel-sel daripada kesan buruk kekurangan serum 
dengan ketara mengekalkan daya maju (cerakin MTT), mengurangkan sel-sel 
apoptotik (pewarnaan Hoescht) dan penanda caspases 3/7, 8 dan 9 (cerakin Caspase) 
 
xxi 
 
mereka. Sifat-sifat perlindungan neuro E. amoenum dalam melemahkan keadaan 
tekanan oksidatif telah disimulasi dengan menguji kapasiti antioksidan menggunakan 
DPPH, ABTS dan ujian pelunturan β-karotena serta kemampuannya untuk 
meningkatkan tahap glutation (GSH) dan glutation-S-transferase (GST). Aktiviti 
IC50 yang radikal masing-masing ialah 10.89 ± 0.082 μg/mL, 15.91 ± 0.10 μg/mL 
dan 9.49 ± 0.12 μg/mL. E. amoenum ekstrak etanol pada 5 μg/mL dengan ketara 
meningkatkan tahap GSH dan GST. Saringan dengan GC/MS mendedahkan jumlah 
fenolik dan flavanoids yang tinggi menyokong sifat mujarab antioksidan. Kesannya 
terhadap angiogenesis telah dinilai melalui cerakin cincin aorta tikus (RARA), 
ekstrak etanol E. amoenum pada 100 μg/mL menghalang daripada 93.22 ± 0.127% 
pembentukan saluran darah dan mengurangkan dengan ketara aktiviti hipoksia yang 
disebabkan faktor kepekatan VEGF dalam Lisat HUVECs daripada 240.89 ± 0.00 
pg/mL hingga 68.15 ± 9.56 pg/mL. Tambahan pula E. amoenum adalah sitotoksik 
terhadap HUVECs dalam cerakin percambahan. Dalam model tikus albino BALB/c 
iskemia neuropati optik, ProSense 750 telah digunakan untuk menyiasat pengaktifan 
katepsin pengantara keradangan dan aktivitinya dipantau menggunakan sistem 
pengimejan in vivo  Tomografi Molekul Pendarfluor (FMT). Tikus dirawat E. 
amoenum (200 and 400mg/kg) mempunyai pengurangan 61.43% dan 75.63% 
daripada iskemia disebabkan gerak balas keradangan masing-masing. E. amoenum 
menunjukkan kesan mujarab perlindungan neuro dalam model in vitro dan in vivo 
degenerasi neuro retina. Ini mungkin disebabkan oleh anti-apoptotik, aktiviti 
antioksidan, keupayaan untuk meningkatkan spesis sel dalaman antioksidan, 
modulasi angiogenesis, dan ciri-ciri anti-radang.  
Keywords: Perlindungan neuro; RGC; Model Tikus Iskemik Neuropati Optik; FMT; 
Echium amoenum L.; Perubatan tradisional.  
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EVALUATION OF NEUROPROTECTIVE PROPERTIES  
OF ECHIUM AMOENUM L. ETHANOLIC EXTRACT 
ABSTRACT  
 
In neurodegenerative diseases, ischemia and hypoxia, oxidative stress, 
excitotoxicity, and inflammation can all lead to neuronal loss. Ganglion cell death as 
a result of optic nerve degeneration can be caused by intermittent ischemic insults 
over defined periods. Neuroprotection aims to prevent, retard or reverse neuronal 
damage as a result of the underlying pathophysiological state. The goal of the present 
work is to evaluate the neuroprotective properties of Echium amoenum L. an Iranian 
native plant. Studies were carried out to deduce whether E. amoenum ethanol extract 
can blunt the negative influences of serum deprivation to retinal ganglion cells 
(RGC-5) in culture and a defined ischemic insult to the optic nerve in mice. Its anti-
apoptotic, antioxidant, angiogenic response and anti-inflammatory activities were all 
investigated. Further studies were then undertaken to screen the active medicinal 
entities present by the use of Gas Chromatography-Mass Spectrometry (GC/MS). 
Petals of E.amoenum chloroform, ethanol, n-hexane, and aqueous extract were 
prepared via maceration technique and screened on RGC-5 for its neurotoxic 
properties. Ethanol and water extracts were non-toxic. However in vitro ischaemia 
studies revealed only the ethanol extract of E. amoenum at 5 µg/mL was effective 
in rescuing RGC-5 cells from the detrimental effect of serum deprivation by 
significantly maintaining viability (MTT assay), decreasing apoptotic cells 
(Hoescht staining) and their markers caspases 3/7, 8 and 9 (Caspase assay). E. 
amoenum ethanol extract neuroprotective properties in attenuating oxidative stress 
conditions was simulated by testing its antioxidant capacities using DPPH, ABTS, 
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and β-carotene bleaching tests and its ability to increase the levels of glutathione 
(GSH) and glutathione-S-transferase (GST). The IC50 of radical scavenging 
activities were 10.89 ± 0.082 µg/mL, 15.91 ± 0.10 µg/mL and 9.49 ± 0.12 µg/mL 
respectively. E. amoenum ethanol extract at 5 µg/mL significantly increased the 
levels of GSH and GST. Screening with GC/MS revealed high amounts of 
phenolics and flavonoids supporting its potent antioxidant property. Its effect on 
angiogenesis was evaluated in SD-Rat aortic ring assay (RARA), E. amoenum 
ethanol extract at 100 µg/mL inhibited of 93.22 ± 0.127% blood vessel formation and 
significantly decreased the activity of the hypoxia induced factor, VEGF 
concentration in HUVECs lysates from 240.89 ± 0.00 to 68.15 ± 9.56 pg/mL. 
Furthermore, E. amoenum ethanol extract was cytotoxic to HUVECs in 
proliferation assay. In albino Balb/c mice ischaemic optic neuropathy model, 
ProSense 750 was used to probe the activation of the inflammatory mediator 
cathepsin and its activity monitored using the Fluorescence Molecular Tomography 
(FMT) in vivo imaging system. E. amoenum ethanol extract treated mice (200 and 
400 mg/kg) had 61.43% and 75.63% reduction of ischaemia induced inflammatory 
response respectively. E. amoenum ethanol extract showed potent neuroprotective 
effect in in vitro and in vivo models of retinal neurodegeneration. This is likely due to 
its anti-apoptotic, antioxidant activity, ability to enhance cellular endogenous 
antioxidant species, modulation of angiogenesis, and anti-inflammatory properties.  
Keywords: Neuroprotection; RGC; Mice Ischaemic Optic Neuropathy Model; 
FMT; Echium amoenum L.; Traditional medicine 
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CHAPTER ONE- LITERATURE REVIEW 
1. Neurodegeneration and Neurodegenerative Diseases- General Definition  
Neurodegeneration is a collective term for the progressive loss of structure, 
function, or even death of neurons. It is a characteristic feature in the pathogenesis of 
diseases as for Alzheimer’s disease, frontotemporal dementia, Parkinson’s disease, 
amyotrophic lateral sclerosis, progressive supranuclear palsy, corticobasal 
degeneration, Huntington's disease, Pick's Disease, prion diseases, motor neuron 
diseases, glaucoma, and also optic neruropathies, etc. (G Kalesnykas, Tuulos, 
Uusitalo, & Jolkkonen, 2008; Stokin & Goldstein, 2006).   
Identified risk factors for neurodegenerative diseases regard in disputable genetic 
polymorphisms and increasing age. Gender, poor education, endocrine conditions, 
oxidative stress, inflammation, stroke, hypertension, diabetes, smoking, head-trauma, 
depression, infection, tumors, vitamin deficiencies, immune and metabolic 
conditions, and chemical exposure are to be other possible causes included (Brown, 
Lockwood, & Sonawane, 2005; Hitzl, Mossler, & Schnait, 2011). The mechanistic 
features of neurodegeneration include aberrant cellular processing, protein 
misfolding and subsequent aggregation of normal proteins and their intracellular or 
extracellular depositions (Doyle et al., 2011; Jucker & Walker, 2013). At the 
molecular level, mechanisms that have been observed include defective neuronal 
plasticity through aberrant regenerative responses, reduced neurotrophin levels, or 
increased neuronal vulnerability to stress (Imitola, Snyder, & Khoury, 2003; Mattson 
et al., 2000).  
Concerning the population of our world which is ageing, also an ever-increasing 
number of elderly are being impacted upon by neurodegenerative diseases. In the 
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developed world, about 2% of the population is afflicted at any time (Hardy & Orr, 
2006; Mattson, Chan, & Duan, 2002). It forecasted that overall number of 
neurodegenerative disease drug market will make a notable growth from around 
US$9 billion in 2005 to more than US$17 billion by 2010 (Fung, 2007; Huss, Spoerri, 
Egger, & Röösli, 2009). Consequently, the overall neurodegenerative diseases 
market has been making the so-called grow at over 12% per year. Therefore, with an 
increase in life expectancy and the number of old people, alongside with advances in 
treatments of neurodegenerative diseases, the increases look set to be continued. 
Central nervous system trauma and neurodegenerative disorders trigger a cascade 
of cellular events resulting in an extensive damage to neurons (Figure 1-1) (Koeppen, 
2008; Magharious, D'Onofrio, & Koeberle, 2011). Regenerative failure is truly a 
critical endpoint to these destructive triggers which are increasingly culminating in 
neuronal apoptosis (Magharious et al., 2011; Mattson, 2006) and inhibition of 
functional recovery.  
 
Figure  1-1 Process of Neuron Degeneration 
Source: (Koeppen, 2008)  
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The non-permissive regenerative environment is due to expression of inhibitory 
cues (Magharious et al., 2011; Winzeler et al., 2011), glial scarring (Silver & Miller, 
2004), slow clearance of axonal debris, and CNS inflammation (Jaerve & Müller, 
2012). Neuronal susceptibility to apoptosis and regenerative failure are crucial 
endpoints of CNS trauma (Figure 1-2).   
 
Figure  1-2 Trauma to the central nervous system 
Source: (Burnett & Zager, 2004) 
Trauma to the central nervous system causes axonal injury leading to disintegrated 
neuronal networks, impaired nerve function, regeneration failure and cell death, 
resulting in long-term neuronal disability.  
 
 
The retina is a division of the central nervous system (CNS), with various types 
of neurons, including photoreceptors, bipolar cells, horizontal cells, amacrine cells 
and retina ganglion cells (RGCs) (Figure 1-3) (Arendt, 2003; Kolb, Nelson, Ahnelt, 
& Cuenca, 2001). The retinal ganglion cells (RGCs) are considered as the output 
neurons of the retina (Boya, 2012). The axons of RGCs, which constitute the last 
stop of the relay, will also be merged to form the optic nerve (Lamb, Collin, & Pugh, 
2007). They transmit signals to the visual centers of the brain (Kolb et al., 2001). 
These visual signals are specifically transmitted from the retina to the lateral 
geniculate nucleus plus superior colliculus (SC) within the brain. Therefore, retina 
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and optic nerve could be affected by similar degenerative processes during 
neurodegeneration (Tezel, 2006; Zhai et al., 2003).  
 
 
 
 
 
 
 
 
Figure  1-3 Retinal Cellular Structure 
Source: (Hagerman & Johnson, 1991) 
 
The optic nerve head appears to be more vulnerable than the rest of the retina, 
probably because the tissue is softer and the inelastic sclera does not cover the 
outside of the eye in this area (Lönngren, 2008). The unproblematic accessibility of 
the optic nerve and the reproducibility of optic neurodegeneration would make it a 
highly effective tool to study CNS trauma and also help in understanding the ensuing 
traumatic events that activate neuronal apoptosis (Lönngren, 2008; Srejić, 2009).  
1.1. Mechanism of Neurodegeneration   
1.1.1. Reduced Neurotrophin   
The neurotrophic hypothesis holds the idea that both mammalian neuronal 
growth and maintenance depend sharply upon the viability of retrograde axoplasmic 
transport of soluble growth factors which are; scientifically speaking, called 
neurotrophins (Agarwal, Gupta, Agarwal, Saxena, & Agrawal, 2009; Bennett, 
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Gibson, & Lemon, 2002; Kaushik, Pandav, & Ram, 2003; Linker, Gold, & Luhder, 
2009; Nave, 2010). It has been shown that increased neurotrophic factor 
concentrations delay or attenuate cell death following injury. The neurotrophins 
supplied to the retinal ganglion cells are small peptides that function in order to 
regulate cellular metabolism by having them attached to neuronal target-cell 
receptors (Gao, Qiao, Cantor, & WuDunn, 2002; Kido et al., 2000; Osborne et al., 
2004). From there, a cascade of molecular enzymatic events and maintain cellular 
homeostasis are being initiated. Ganglion cells appear to be particularly dependent 
upon the brain-derived neurotrophin factor which necessarily is vital for their 
continued survival (Nave, 2010; T. Su, 2010). This factor is able to promote survival; 
furthermore, prevent neuronal death after axotomy in the optic nerve (Koeberle, Tura, 
Tassew, Schlichter, & Monnier, 2010). Further support for the neurotrophic 
hypothesis comes from the findings of Gao et al  showing that an enhanced 
expression of brain-derived neurotrophin factor in the RGC layer takes place after 
the optic nerve injury (Kaushik et al., 2003; Kuehn, Fingert, & Kwon, 2005; Seki et 
al., 2005).  
1.1.2. Excitotoxicity and Glutamate Release 
In the pathology of a list of neurodegenerative disorders regarding the brain, 
excitotoxicity has been implicated as forth, Alzheimer’s, Parkinson’s, Huntington’s 
disease and amyotrophic lateral sclerosis (Mattson, 2008; Swartz, Linn, & Linn, 
2013). Neurodegenerative diseases of the eye, considering glaucoma, retinal 
ischemia, and diabetic retinopathy, also have pathologies associated with 
excitotoxicity (K.-G. Schmidt, Bergert, & Funk, 2008; Seki & Lipton, 2008; Swartz 
et al., 2013). Excitotoxicity is the excessive stimulation of neurons by excitatory 
amino acids such as glutamate, aspartate and quisqualate through postsynaptic 
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receptors. Glutamate serves as a neurotransmitter at most CNS synapses. Ironically, 
in addition to being the main neurotransmitter involved in excitotoxicity in mammals, 
glutamate is also the most prevalent neurotransmitter in the mammalian brain, being 
utilized in varying degrees by nearly all neurons of the vertebrate central nervous 
system  and exposure to high concentrations has shown to have apoptosis of cells 
brought forththrough a process of excitotoxic cell death in a variety of model systems, 
giving rise to the very term which is called the glutamate-induced excitotoxicity 
(Mattson, 2003; Swartz et al., 2013). This so-called matter occurs when the oxygen 
and glucose supply in the brain has been dramatically decreased in cases where blood 
flow ceases; for instance, during a stroke.  
Regarding a number of reports indicating that the neurotoxic effects of ischemia 
and hypoxia on the brain and retinal tissue result directly from an increase in the 
concentration of amino acid neurotransmitters, most notably to name glutamate. It 
has been confirmed that in both brain and retina, the levels of glutamate are being 
increased due to experimentally induced ischemia or hypoxia.  
Certain pathological conditions can cause excessive glutamate to be released, 
however under normal circumstances glutamate from the synaptic cleft is 
reaccumulated immediately into the nerve terminal or into adjacent glia, which holds 
glutamine synthetase that would have glutamate converted into glutamine. 
Possessing a similar plasma membrane glutamate uptake carrier, glial cells and 
neurons keep the extracellular glutamate concentration below levels that damage 
neurons (Inage, Itoh, Wada, Hoshika, & Takashima, 2000). 
The self-reinforcing deleterious action of glutamate receptor stimulation also 
produces an influx of sodium and calcium ions plus further membrane depolarization. 
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The influx of Na+ is accompanied with the influx of chloride and the osmotically-
driven influx of H2O, resulting in cellular swelling. This early phase of excitotoxic 
injury is followed by activation of several types of cell receptors, including N-
methyl-D-aspartate receptors that can allow entry of excessive amounts of calcium.  
In ischemic neuronal injury, the loss of calcium homeostasis plays a critical role in 
neuronal death. Abnormally calcium overload leads to sustained activation of a 
number of calcium-dependent enzymes, including protease, endonucleases and lipid 
peroxidases, they straightly attack cell constituents which leads to the generation of 
highly reactive free radicals plus the activation of the nitric oxide pathway (Naskar & 
Dreyer, 2001). DNA nitrosylation, fragmentation and activation of the apoptotic 
program turn out of the resulting interaction between intermediate compounds and 
free radicals (Wei et al., 2000; Z. Zheng, Lee, & Yenari, 2003).  
1.1.3. Free Radical Generation 
Being unstable, and having highly reactive molecules are distinctive features of 
free radicals characterized by the presence of unpaired electrons in their outermost 
shells (Halliwell, 2005). Usually, electrons associated with atoms or molecules are 
paired because this makes atoms relatively stable and unreactive. The loss of an 
electron leaves a molecule much more reactive than its paired counterpart. In case 
two radicals react, both radicals are eliminated; while if a radical reacts with a non-
radical, another free radical is; thus, produced. Allowing free radicals to participate 
in chain reactions, this characteristic may be thousands of events long. According to 
Williams and Jeffrey (Si et al., 2011; G. M. Williams & Jeffrey, 2000), reactive free 
radicals or reactive oxygen species, such as superoxide anion, hydroxyl radical and 
peroxyl radical are particularly reactive and known to be a biological product of 
reducing molecular oxygen or metabolic processes.  
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Ischemia causes a net increase in free radicals, overwhelming the antioxidant 
capabilities and contributing to ischemia/reperfusion injury in the retina (Shibuki, 
Katai, Yodoi, Uchida, & Yoshimura, 2000), particularly in the early reperfusion 
period when flow is restored to energy-depleted tissue. Generation of free radicals 
are not only through the activation of glutamate receptors but it also is an inevitable 
by-product of normal oxidative mechanisms (Halliwell, 2001). Specially, this is true 
in the retina which owns a very high metabolic rate. These free radicals are normally 
being inactivated by endogenous antioxidants such as superoxide dismutase, 
Vitamins E and C, and glutathione. However, worthy to be mentioned, when not 
inactivated sufficiently, the so-called free radicals can react detrimentally with most 
macromolecular cellular constituents resulting in one: the disruption of membrane 
fluidity, two: protein denaturation, three: lipid peroxidation, four: oxidative DNA and 
finally: alteration of platelet functions (D.-O. Kim, Jeong, & Lee, 2003).  
1.1.4. Oxidative Stress   
Oxygen is essential to life and it plays an essential role in variety of 
biological phenomena, however, it can also provoke damaging oxidative events 
within cells. There is a variety of free radicals given rise to by molecules, those that 
are produced from molecular oxygen have received the most investigative interest, 
though (Apel & Hirt, 2004). Due to their higher reactivity relative to molecular 
oxygen, partially reduced metabolites of molecular oxygen (O2) are referred to as 
“reactive oxygen species (ROS)” (Tezel, 2006). ROS includes molecules such as 
superoxide anion, hydrogen peroxide (H. A. Jung et al., 2008), hydroxyl radical, 
nitric oxide, peroxyl radical and singlet oxygen (S. Jung et al., 2008), are generated 
as by-products of normal aerobic metabolism or, in other words, as secondary 
messengers (Choi, Kim, Kim, Yoo, & Chon, 2006) in various signal transduction 
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pathways (Choi et al., 2006). An increase over physiological values in the 
intracellular concentrations of ROS is defined as oxidative stress. At the time when 
there are changes in the endogenous activity of antioxidant enzymes, this situation is 
being initiated (e.g. catalase, glutathione, superoxide dismutase, metallothionein) 
and/or at the time of the concentrations regarding certain vitamins (S. Jung et al., 
2008; Mostafa, 2006). 
Excessive ROS are cytotoxic, as they disturb intercellular homeostasis and impair 
the mitochondrial transport chain, thus inducing cell death. Mitochondria comprises 
the greatest amount of ROS, since the mitochondrial transport chain consumes 85% 
of oxygen that the cell utilizes. Once generated, ROS inhibit complex enzymes in the 
electron transport chain, resulting in an enhancement of ROS production and a 
shutdown of mitochondrial energy production. Energy depletion causes failure of 
many ATP-reliant processes in the cell and destroys cell integrity. Moreover, ROS 
activates mitochondria-mediated apoptosis pathway, leading to DNA breakdown 
(Bayr, 2005; Sena & Chandel, 2012). Oxidative stress has been suggested to have the 
pathogenesis of age-related macular disease contributed to (Jarrett & Boulton, 2012; 
Virgili, Do, Bressler, & Menchini, 2007). Not only because of photochemical 
reactions the photoreceptors of the retina are particularly susceptible to oxidative 
damage (Chrysostomou, Rezania, Trounce, & Crowston, 2013) but also because of 
their high content of polyunsaturated fatty acid (B. Zhang & Osborne, 2006) and rich 
supply of oxygen from the choroidal circulation (B. Zhang & Osborne, 2006). 
Support for the involvement of oxidative stress in age-related macular degeneration 
(AMD) springs from the finding which notices that daily administration of 
antioxidant vitamins and/or zinc significantly decelerates the rate of progression in 
specially patients from high risk atrophic age-related macular degeneration to 
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neovascular age-related macular degeneration (Fawcett & Osborne, 2007). Another 
compelling piece of evidence, moreover, stems from mass spectroscopy of drusen 
(deposits) from postmortem eyes of patients with age-related macular degeneration, 
which showed many oxidized proteins (Crabb et al., 2002; Fawcett & Osborne, 
2007). A causative role in glaucoma has also been suggested to be played by 
oxidative stress (Mozaffarieh, Grieshaber, Orgül, & Flammer, 2008). As the neurons 
in glaucoma are at a low energetic state, the scavenging system may not be efficient 
enough to remove cell metabolites, thus accumulating waste products and generating 
ROS. Also, substantial evidence exists to bear the suggestion that oxidative stress 
plays a major part in the pathogenesis of glaucoma or glaucomatous optic neuropathy 
(Izzotti, Bagnis, & Saccà, 2006).  
1.1.4.1. GSH is a Key Endogenous Antioxidant  
To name, one of the crucial modulators of cell survival, under both normal and 
pathological conditions, that would be the endogenous antioxidant tri-peptide 
glutathione (GSH, γ-glutamyl-L-cysteinyl-glycine) (Circu & Aw, 2012; Franco, 
Schoneveld, Pappa, & Panayiotidis, 2007). The involvement of GSH exists in many 
essential cell processes, for instance, DNA synthesis and cell metabolism, yet acting 
as an antioxidant and scavenger of ROS is its primary function (G. Wu, Fang, Yang, 
Lupton, & Turner, 2004). There is a reduced and active state GSH exists and is also 
oxidized to glutathione disulfide (GSSG) upon unstable molecules being reduced, 
such as ROS. The reduction of ROS by GSH is facilitated by the enzyme GSH 
peroxidase (GPx) (Dringen, Gutterer, & Hirrlinger, 2000; Takahashi, 2012). The 
enzyme, glutathione reductase (GR), then returns GSSG to its reduced form GSH 
(Figure 1-4).  
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Figure  1-4 Glutathione metabolism 
Source: (Circu & Aw, 2012; G. Wu et al., 2004) 
 
There exist two distinct steps in biosynthesis of GSH to happen. The first so-
called step occurs when γ-glutamylcysteine ligase (GCL) has glutamate and cysteine 
combined together. This reaction is, in GSH synthesis, called the rate-limiting step. 
The second step to be explained in GSH synthesis comes about when GSH 
synthetase adds up glycine to the C-terminus of the end product of the first step, that 
is to say, γ-glutamylcysteine. The rate-limiting precursor in GSH synthesis is named 
Cysteine (Figure 1-5) (G. Wu et al., 2004). Since its potent antioxidant activity plus 
its neuroprotective capacity have been demonstrated in many in vitro and in vivo 
systems, strategies that enhance GSH synthesis draws attention as potentially novel 
therapies regarding neurodegenerative diseases.  
 
Figure  1-5 Glutathione synthesis 
Source: (G. Wu et al., 2004) 
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1.1.5. Apoptosis 
Apoptosis and Necrosis are two distinct mechanisms of cell death, with very 
different characteristics. In general, necrosis is less organized than apoptosis. Figure 
1-6 gives a brief outline of differences between necrosis and apoptosis.  
 
Figure  1-6 Schematic views of the differences between apoptosis and necrosis  
Retrieved from: http://www.pasteur.be/pasteur_en 
Date of access: July, 10, 2014  
 
Necrotic cell death is caused by the following matters: injury, infection, cancer, 
infarction and lastly inflammation. In necrosis, cells swell and cytoplasmic 
organelles are injured, plus random DNA fragmentation which leads to uncontrolled 
release of enzymes having been stored by lysosomes with a rapid collapse of internal 
homeostasis. The initiation of cell damage may take place by a reaction due to the 
membrane lysis and subsequent release of cellular contents that can put surrounding 
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cells in danger. Unlike apoptosis, the association between necrosis and inflammation 
is positive (Vanden Berghe et al., 2013).  
 Apoptosis, or programmed cell death, is energy-dependent and is executed in 
such a way as to safely dispose of dead cells and their fragments. In contrast to 
necrosis, apoptosis is carried out in a well ordered process and generally confers 
advantages during an organism’s life cycle. Following an initial insult, the cells try to 
minimize or buffer the damage done through a variety of processes. Generation of 
“suicide triggers” could be one of the consequences of these processes and 
interactions and these molecules may start the process of apoptosis which is 
characterized by an orderly pattern of inter-nucleosomal DNA fragmentation, 
chromosome clumping, cell shrinkage and membrane blebbing (Farkas & 
Grosskreutz, 2001). This is followed by disassembly of cells into multiple 
membrane-enclosed vesicles that are engulfed by neighboring cells without inciting 
inflammation.  
Up to now two apoptosis pathways have already been described and 
distinguished, the intrinsic pathway and the extrinsic one. They are initiated by 
different factors and thus have different biochemical changes, yet both share the 
same consequences of caspase-3 activation and DNA fragmentation as shown in 
Figure 1-7.  
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Figure  1-7 Proposed interaction between intrinsic and extrinsic apoptotic pathways 
Source: (Schon & Manfredi, 2003)  
 
1.1.5.1. Extrinsic Pathway (Receptor Pathway) 
The activation of membrane receptors is the involvement seen in the extrinsic 
pathway (Figure 1-7). The death signal concerns the binding of extracellular death 
ligands, such as FAS, glutamate, nitric oxide or tumor necrosis factor-α, which are 
released by malfunctioning cells, as proposed to be occurred in the region of the 
optic nerve head (Morgan, 2000; Osborne, Melena, Chidlow, & Wood, 2001), in the 
initiation of glaucoma.  
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Such extracellular stimuli can have the intracellular biochemical pathways 
activated which causes an increase in ROS, then reacts chemically with various 
targets within the cell in order to elicit a chain of events that is often regulated by the 
tumour suppressor gene p53. The p53 protein can then alter the expression of several 
other genes which eventually lead to the catabolic enzymes activation, particularly 
those that degrade the cellular DNA (nucleases) and proteins (proteases). The death 
receptors transmit signals to the interior of the cells and recruit procaspase-8, which 
can be auto-activated by aggregation to caspase-8. Then, this activates procaspase-3 
resulting in apoptosis. This process whereby extracellular signals, for instance, 
glutamate which can stimulate ganglion cell death has been known as the extrinsic 
pathway of apoptosis (Wajant, 2002, 2003).  
1.1.5.2. Intrinsic Pathway (Mitochondria-Dependent Pathway) 
In most cell types, however, caspase-8 first cleaves BH3-interacting domain 
death agonist, the B cell lymphoma 2 family protein, which, in turn, induces the 
translocation, oligomerization, and also insertion of the other family members, BCL-
2-associated X protein and/or BCL-2 antagonist or killer, into the outer 
mitochondrial membrane (OMM). This is, then, followed by permeabilization of the 
outer mitochondrial membrane plus the release  of  several  proteins  from the 
mitochondrial  intermembrane space,  including cytochrome c, which forms a 
cytosolic apoptosome complex with apoptosis having factor-1 (Apaf-1) and 
procaspase-9 activated (Figure 1-8).  
This results in the activation of procaspase-9, which consequently leads to the 
activation of procaspase-3 and other effector caspases. The distinctive feature 
regarding this so-called pathway would be the involvement of the mitochondria. 
Triggering events within the cell to have mitochondria affected can be stress signals 
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and/or loss of survival signals. The intrinsic pathway would be either caspase-
dependent or caspase-independent.  
 
 
Figure  1-8 General apoptotic pathways 
Source: (Orrenius, 2007)  
 
1.1.6. Hypoxia   
As the final electron accepter of aerobic respiration, molecular oxygen is 
essential for the survival of most metazoans. Oxygen deprivation (hypoxia) is often 
involved in development, homeostasis and many other diseases (Correia & Moreira, 
2010; Grimm et al., 2005; Ogunshola & Antoniou, 2009). Multi-cellular organisms, 
in order to adapt to hypoxia, have evolved complex networks that have metabolic 
changes regulated in both systemic and cellular levels to mediate changes in 
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angiogenesis/vascular remodeling, glycolytic metabolism plus cell proliferation 
(Correia & Moreira, 2010; Grimm et al., 2005; Hopkins & Powell, 2001). The 
oxygen tension-dependent transcriptional factor, hypoxia inducible factor-1 (HIF-1), 
holds the responsibility for the induction of genes which is responsible to facilitate 
the adaption and survival of cells exposed to hypoxia. HIF-1 activation induces a 
diverse range of target genes, encompassing a wide variety of cellular processes, 
including angiogenesis, erythropoiesis, energy metabolism, cell proliferation, and 
cell cycle control (Ke & Costa, 2006; Schumacker, 2005). HIF-1 can improve the 
redox environment (Guo, Miyake, Liu, & Shi, 2009), increase blood oxygen plus 
glucose supply, and have an effect on iron metabolism by regulating its target genes. 
The brain consumes a large quantity of oxygen and demonstrates a high vulnerability 
at conditions with impaired oxygen supply. It has been noticed that reduced oxygen 
supply plays an influential role in neurodegeneration during the aging process 
(Ogunshola & Antoniou, 2009). Oxidative stress, impaired oxygen or glucose supply, 
and disruption of iron homeostasis would all be considered as pathological processes 
which are common in neurodegenerative diseases (Benarroch, 2009; Correia & 
Moreira, 2010; Gironi et al., 2010). This makes up the very possibility that HIF-1 
could be a potential therapeutic target for these neurodegenerative diseases.  
1.1.6.1. Hypoxia-Induced Factor (HIF)  
Simple diffusion of oxygen to metabolizing tissues beyond a size limitation 
has become inadequate; furthermore, specialized systems of increasing complexity 
have evolved to meet the demands of oxygen delivery higher in animals (Pugh & 
Ratcliffe, 2003). One important role in the systems is angiogenesis, to make new 
vessels sprouting into the location that blood delivery is being needed. Thus, one of 
the key factors which would lead to the initiation of angiogenesis is ischemia or 
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hypoxia. Yet how hypoxia exactly induced angiogenesis is however poorly 
understood. The landmark of hypoxia study in the early 1990s indicated that hypoxia 
could only induce expression of platelet-derived growth factor (PDGF) mRNA and 
vascular endothelial growth factor (VEGF) mRNA in tissue culture. Both platelet-
derived growth factor (PDGF) and VEGF are thought to be crucial growth factors 
triggering angiogenesis. A large number of genes are engaged in diverse steps in 
angiogenesis and they also are independently responsive to hypoxia in tissue culture. 
Besides platelet-derived growth factor and VEGF, nitric oxide synthase, fibroblast 
growth factor, angiopoietins, and matrix metalloproteinases are involved. Cell 
migration or endothelial tube formation which are of the individual phenotypic 
processes in angiogenesis can be induced by hypoxia tissue culture (Krishnamachary 
et al., 2003).  
Further study of hypoxia-induced angiogenesis leaded to the discovery of a key 
transcriptional regulator, hypoxia-inducible factor (HIF)-1. The molecular 
mechanism behind HIF-1 is a pathway which has oxygen availability plus the gene 
expression of several different growth factors linked, especially VEGF. In normoxia 
and hyperoxia oxygen-dependent prolyl hydroxylases hydroxylate HIF-1 α proline 
residues, and this chemical modification leads to a HIF-1 capture by an ubiquitin 
ligase complex that directs it to the proteasome for destruction. Under hypoxic 
conditions, HIF-1α is not hydroxylated, escapes ubiquitination, accumulates and 
directs pro-angiogenic expression (Maxwell & Ratcliffe, 2002).  
1.1.7. Role of Neuroinflammation  
Neuroinflammation and protein aggregates pathology (e.g. amyloid plaques, 
Lewy Bodies) are another theory which explains the cause of neurodegeneration 
(Frank-Cannon, Alto, McAlpine, & Tansey, 2009; Khandelwal, Herman, & Moussa, 
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2011). Based on this theory, following stimuli, specifically protein aggregates for 
instance, amyloid plaques, the neuroinflammatory cycle is generated followed by 
microglia and astrocytic activation (Skaper, 2007). Controlled biosynthesis, 
maturation, function and terminal breakdown of proteins are factors that play crucial 
role in maintenance of a healthy organism (Reiser, Adair, & Reinheckel, 2010). 
Proteolytic enzymes donate all the above processes irreversible cleavage of peptide 
bonds in a polypeptide chain by a nucleophilic attack on the carbonyl carbon. The 
proteases are acting in two ways by either cleaving one or a few amino acids at the N 
or C terminus, which called exopeptidases protease or endopeptidases one, cleaving 
internal peptide bonds (Barrett & Rawlings, 2007; Puente, Sánchez, Overall, & 
López-Otín, 2003). Endopeptidases are classified, in terms of their catalytic 
mechanism, into threonine, aspartic, metallo, serine and cysteine endopeptidases 
(Vos et al., 2000). The latter, cysteine proteases, form the largest cathepsin family. 
The human family of cysteine cathepsins comprises cathepsins B, C (also known as 
cathepsin J and dipeptidyl-peptidase 1), F, H, K (also known as cathepsin O2), L, O, 
S,W, V (also known as cathepsin L2), and X (also known as cathepsin Z and 
cathepsin P), which share a conserved active site formed by cysteine, histidine and 
asparagines residues (Rawlings, Barrett, & Bateman, 2012).  
Cysteine cathepsins are synthesized as inactive precursors, normally activated in 
the acidic environment of lysosomes. Therefore, they were initially considered as 
intracellular enzymes, responsible for the non-specific, bulk proteolysis in the acidic 
environment of the endosomal/lysosomal compartments, where they degrade 
intracellular and extracellular proteins (B. Turk, Turk, & Turk, 2000; V. Turk, Turk, 
& Turk, 2001). Furthermore, they are involved in proteolytic processing of specific 
substrates. Cathepsin plays an important role in protein, neuropeptide and hormone 
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processing (Funkelstein, Toneff, Hwang, et al., 2008; Funkelstein, Toneff, Mosier, et 
al., 2008), major histocompatibility complex (MHC) classII-mediated antigen 
presentation (Honey & Rudensky, 2003), bone remodeling (Yasuda, Kaleta, & 
Brömme, 2005), apoptosis (B. Turk et al., 2002) and to keratinocyte differentiation. 
Apart their normal physiological roles, cysteine cathepsins are involved in several 
pathologies, such as tumour development and progression , inflammation (Conus & 
Simon, 2008), psoriasis , muscular dystrophy, atherosclerosis (J. Liu et al., 2006), 
rheumatoid arthritis (Yasuda et al., 2005), osteoporosis and other bone disorders 
(Conus & Simon, 2008; J. Liu et al., 2006; Stoch & Wagner, 2007; Yasuda et al., 
2005), acute pancreatitis (Halangk et al., 2000) and neurodegeneration (Nakanishi, 
2003b). 
It is extensively well-accepted that overexpression, increased enzymatic activity 
and mis-localization of cysteine cathepsins in cells of the nervous system are 
associated with pathological processes in neurodegenerative disorders (Hook, 2006; 
Lynch & Bi, 2003; Yamashima, 2000). Dysfunction of the endosomal/lysosomal 
system in neurons is closely associated with activation of microglia, which could 
initiate an inflammatory response to provoke neurodegeneration. Activated microglia 
also releases certain cathepsins that induce neuronal death through degradation of 
extracellular matrix proteins (Figure 1-9) (Nakanishi, 2003a; Pišlar & Kos, 2014). 
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Figure  1-9 Cysteine cathepsins involvement in neurodegeneration and inflammation-
induced neurodegeneration 
Source: (Pišlar & Kos, 2014)  
Lysosomal cysteine cathepsins can be altered by many toxic insults leading to 
enhanced cathepsin expression and proteolytic activity, which contribute to neuronal 
injury during neurodegeneration. Activated microglia mediate neuroinflammation by 
secreting inflammatory cytokines thereby, inducing neuronal death. In addition to 
cytokines, activated microglia secretes certain cathepsins thus upscaling 
inflammation-induced neurodegeneration.  
 
 
During neurodegeneration, cathepsins contribute to neuronal injury induced by 
excitotoxins, through degradation of axonal and myelin proteins, by converting 
protein precursor into active peptide neurotransmitters and by amplifying apoptotic 
signaling (Haque, Banik, & Ray, 2008; Hook, 2006). Furthermore, a central role in 
the neuronal cell death mechanism has been proposed for cathepsins (Stoka, Turk, & 
Turk, 2005). In terms of which cysteine cathepsins are specifically involved in 
neurodegeneration, cathepsins B and L have been investigated most intensively. 
They have been reported to induce age-related changes that are closely related to 
neuronal degeneration (Yamashima, 2000). Due to the harmful action of cysteine 
cathepsins in pathological processes of neurodegeneration (Benchoua, Braudeau, 
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Reis, Couriaud, & Onténiente, 2004; Chwieralski, Welte, & Bühling, 2006), 
cathepsin inhibitors constitute a possible tool for therapeutic interventions to inhibit 
excessive proteolytic activity (Haque et al., 2008; Stoch & Wagner, 2007). Some 
beneficial effects of cystatins have been demonstrated; however, they are general 
inhibitors, not selective for particular cathepsins therefore, and off-target side effects 
are expected if they are used as drugs for treating patients. Instead of cystatins and 
other endogenous cysteine protease inhibitors therefore, synthetic cathepsin 
inhibitors have been suggested as agents for treating neurodegenerative disorders 
(Booth, 2012; Pišlar & Kos, 2014; Tyynelä et al., 2000).  
1.2. The Anatomy of the Eye  
Optically working like a film camera, the eyes of all the vertebrates are 
structurally similar. The light enters the eye through the pupil and forms an inverted 
image on the retina, the light-capturing component that functions like the film in a 
camera (Drack, 2006). The cornea and the lens help to focus so that the clearest 
image is presented on the retina. The white outer surface of the eye ball is termed 
sclera, which consists of tough but flexible fibrous tissue and provides the 
mechanical support of the entire eye. The choroid is a layer contained within the 
sclera, and it is a dense meshwork of blood vessels and other tissues. One of the most 
important functions of the choroid is to provide nutritional and metabolic support for 
the retina, which is a neuronal sheet that lies within the choroid. The retina is the 
most inner surface at the back of the eye. Most of the space in the eye is filled with a 
gelatinous body, called vitreous. It is surrounded by the lens and the retina and the 
ciliary body. In the ciliary body, the cells secrete the aqueous fluid into the eye, 
which contributes to the maintenance of the pressure within the eye (Irsch & Guyton, 
2014; Purves et al., 2001).  
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1.2.1. The Retina  
The retina, a layer about 0.4 mm in thickness, is primarily composed of 
neural tissue including five classes of neurons. It spreads out on the interior surface 
of the back of the eye (Figure 1-10). The visual pathway is initiated when the light 
stimulates the photoreceptors that are embedded in the outer retinal layers. The signal 
is transmitted to bipolar cells and then to ganglion cells. The signal then travels along 
the axon of the ganglion cells lining inner nuclear layer, respectively, while amacrine 
cells contact with bipolar axons primarily in the inner plexiform layer (Boya, 2012; 
Rabin, 2013).   
 
Figure  1-10 Basic structure of human eye  
Retrieved from: http://www.nei.nih.gov 
Date of access: July, 21, 2014 
 
Light passes through almost the whole thickness of the retina to be captured by 
photoreceptors, or the outer segments of the photoreceptor in detail, where the visual 
pigment molecules for light capturing are located. There are two types of 
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photoreceptors, rods and cones (Boya, 2012). Rods are specialized to convey 
variations in light intensity in dim conditions, but they are not able to function in 
bright light. Cones are specialized for bright light conditions, but they are not as 
sensitive as rods. The retina cross section can be divided into multiple layers. The 
nuclear layers are basically where cell nuclei are located, and the synaptic layers are 
the place where cells communicate and transmit electric or chemical signals. The 
retinal pigment epithelium (RPE) functions as the outer blood-retinal barrier (BRB) 
that shut off the diffusion of large molecules from choroicapillaries. And the retinal 
vasculature doesn’t grow beyond the inner limiting membranes under normal 
physiological conditions.  
1.2.2. Retinal Ganglion Cells 
The innermost neuronal layer of the retina is where the retinal ganglion cells 
are located in. The axons of the retinal ganglion cells form the nerve fiber layer 
(stratum opticum) which is situated on top of the retinal ganglion cell soma, next to 
the side of the vitreous. These axons conjoin in the central retina as optic nerve head 
and thus form thereafter the optic nerve, which extend after the optic chiasm as optic 
tract in the optic center of the brain (Provencio, Rollag, & Castrucci, 2002). Different 
subpopulations of retinal ganglion cells exist (Vaney, Sivyer, & Taylor, 2012) which 
use different neurotransmitter gamma-aminobutyric acid (GABA), glycine or 
glutamate (Iuvone, 2012). The retinal ganglion cells, apart from sending 
photoreceptor derived signal into the optic center of the brain, perform different 
functions. For instance, photosensitive retinal ganglion cell are involved in the 
pupillary reaction and circadian rhythm (Lucas, Douglas, & Foster, 2001; T. M. 
Schmidt, Chen, & Hattar, 2011).  
